Armed oncolytic viruses: A kick-start for anti-tumor immunity

Abstract

Oncolytic viruses (OVs), viruses that specifically result in killing tumor cells, represent a promising class of cancer therapy. Recently, the focus in the OV therapy field has shifted from their direct oncolytic effect to their immune stimulatory effect. OV therapy can function as a "kick start" for the antitumor immune response by releasing tumor associated antigens and release of inflammatory signals. Combining OVs with immune modulators could enhance the efficacy of both immune and OV therapies. Additionally, genetic engineering of OVs allows local expression of immune therapeutics, thereby reducing related toxicities. Different options to modify the tumor microenvironment in combination with OV therapy have been explored. The possibilities and obstacles of these combinations will be discussed in this review.

Cited by papers we hold 4

• Glioblastoma Therapy: Past, Present and Future · 2024
  No notice
• Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes · 2021
  No notice
• Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy · 2021
  No notice
• Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment · 2020
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.